Clinical Trials
167 trialsNCT05068752 2026-03-30
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT00989469 2026-02-05
NEXIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT01715441 2026-02-05
NEXIRI2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT03211416 2026-02-05
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00826540 2026-01-20
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT06797427 2025-03-17
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
Disruptive Pharma
Phase EARLY_PHASE1 Completed
NCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT03439891 2025-02-11
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
University of California, San Francisco
Phase 2 Completed
NCT03009461 2024-12-04
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
Peking University
Phase 2 Completed
NCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03606590 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
NovoCure Ltd.
Phase 2 Completed
NCT01906216 2024-08-28
SELECT
Air Force Military Medical University, China
Phase 3 Completed
NCT02856126 2024-07-23
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT04763408 2024-07-18
STELLAR
Eisai Inc.
Completed
NCT04518852 2024-06-25
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT06030895 2024-03-12
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Damanhour University
Phase NA Completed
NCT01004978 2024-01-03
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01624285 2023-12-14
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT00813293 2023-06-13
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT02349867 2022-09-19
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00981162 2022-09-13
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Phase 1 Completed
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT01015833 2022-08-04
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02072486 2022-07-25
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase NA Completed
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT02354898 2022-04-12
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT02358395 2022-04-12
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT02178358 2022-02-25
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01900002 2021-12-30
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05121571 2021-11-26
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
NCT00844883 2021-11-11
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Yale University
Phase 2 Completed
NCT00892658 2021-10-06
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
University Health Network, Toronto
Phase 1 Completed
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01271504 2021-05-12
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1/2 Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT01915602 2021-04-08
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Bayer
Phase 2 Completed
NCT02642913 2021-03-05
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01666756 2021-01-27
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed